UBS Group
ZNTL icon

UBS Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

UBS Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$364K Sell
155,704
-518,894
-77% -$1.34M ﹤0.01% 6298
2025
Q4 		$911K Buy
674,598
+141,920
+27% +$207K ﹤0.01% 5655
2025
Q3 		$804K Buy
532,678
+403,210
+311% +$604K ﹤0.01% 5735
2025
Q2 		$150K Sell
129,468
-12,468
-9% -$16.4K ﹤0.01% 6916
2025
Q1 		$226K Sell
141,936
-41,742
-23% -$90K ﹤0.01% 6467
2024
Q4 		$557K Buy
183,678
+154,150
+522% +$505K ﹤0.01% 5763
2024
Q3 		$109K Sell
29,528
-77,572
-72% -$282K ﹤0.01% 6296
2024
Q2 		$438K Sell
107,100
-160,765
-60% -$1.8M ﹤0.01% 5099
2024
Q1 		$4.22M Buy
267,865
+267,755
+243,414% +$3.68M ﹤0.01% 3155
2023
Q4 		$1.67K Sell
110
-66,723
-100% -$973K ﹤0.01% 8249
2023
Q3 		$1.34M Sell
66,833
-22,920
-26% -$582K ﹤0.01% 3831
2023
Q2 		$2.53M Buy
89,753
+6,344
+8% +$152K ﹤0.01% 3302
2023
Q1 		$1.43M Sell
83,409
-71,483
-46% -$1.45M ﹤0.01% 3766
2022
Q4 		$3.12M Buy
154,892
+129,897
+520% +$2.79M ﹤0.01% 2937
2022
Q3 		$542K Sell
24,995
-4,848
-16% -$133K ﹤0.01% 4266
2022
Q2 		$839K Sell
29,843
-44,412
-60% -$1.18M ﹤0.01% 3871
2022
Q1 		$3.43M Buy
74,255
+38,749
+109% +$2.09M ﹤0.01% 2929
2021
Q4 		$2.98M Buy
35,506
+35,241
+13,298% +$2.73M ﹤0.01% 3360
2021
Q3 		$18K Buy
265
+10
+4% +$577 ﹤0.01% 7298
2021
Q2 		$14K Buy
+255
New +$13.7K ﹤0.01% 7723
2021
Q1 		– Sell
-182
Closed -$9K – 9553
2020
Q4 		$9K Buy
+182
New +$8.21K ﹤0.01% 7580
2020
Q3 		– Sell
-257
Closed -$12K – 8467
2020
Q2 		$12K Buy
+257
New +$9.86K ﹤0.01% 6904

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

UBS Group's ZNTL Position: Q1 2026 in Review

UBS Group reduced its Zentalis Pharmaceuticals (ZNTL) stake by 77% in Q1 2026, selling an estimated $1.34M and leaving 155,704 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #6298.

UBS Group first reported a position in ZNTL in Q2 2020 and has held it in 22 quarters since. The position peaked at $4.22M in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • UBS Group held 155,704 shares of Zentalis Pharmaceuticals worth $364K as of Q1 2026.
  • UBS Group sold 518,894 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.34M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6298 holding.
  • UBS Group first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • UBS Group's Zentalis Pharmaceuticals position peaked at $4.22M in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.